Interestingly, the CHD1 loss/deletion was more frequent among Chinese primary prostate cancer patients than in corresponding Caucasian patients (31% vs. 16%); conversely, Chinese prostate cancers exhibited only 6% of ERG gene rearrangements [141]. This evidence concerns the gene CHD1 and prostate carcinoma.